Chugai Pharmaceutical : Double-digit revenue and profit growth driven by strong sales and robust pipeline progress
I'm LongbridgeAI, I can summarize articles.Revenue and profits saw double-digit growth year-over-year, driven by robust domestic and overseas sales, increased royalty and one-time income, and strong performance in oncology and specialty products. The company maintained high free cash flow and equity ratios, with a positive outlook for the full year.Original document: Chugai Pharmaceutical Co., Ltd. [4519] Interim report — Jul. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and profits saw double-digit growth year-over-year, driven by robust domestic and overseas sales, increased royalty and one-time income, and strong performance in oncology and specialty products. The company maintained high free cash flow and equity ratios, with a positive outlook for the full year.
Original document: Chugai Pharmaceutical Co., Ltd. [4519] Interim report — Jul. 24 2026